(Source: Xencor Inc) MONROVIA, Calif., May 11, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that data from the Phase 1b/2a study of XmAb®5871 will be featured in a poster presentation at The European League Against Rheumatism (EULAR) 2015 annual meeting taking place in Rome, Italy. Abstract # FRI0161 Title: A Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis Authors: M. Jaraczewska-Baumann, M. Korkosz, G. Sulyok, P....
↧